Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Ocular Therapeutix Inc's Business Segments
Ocular Therapeutix Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
$ 11
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Single Reportable Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | $ 11 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product100%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 11 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Ocular Therapeutix Inc
Ocular Therapeutix Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for eye diseases and conditions. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Ocular Therapeutix is primarily known for its sustained-release drug delivery platform, which enables the precise and controlled release of drugs into the eye over an extended period of time. This platform, known as the hydrogel-based technology, has the potential to revolutionize the way eye diseases are treated by eliminating the need for frequent dosing and improving patient compliance.
The hydrogel-based technology utilizes a biocompatible and bioerodible polymer that forms a gel-like matrix upon contact with tears in the eye. Drugs are then incorporated into this matrix, allowing for sustained release as the matrix gradually erodes. This approach can provide continuous drug delivery for weeks or even months, depending on the specific drug and condition being treated.
One of the flagship products developed by Ocular Therapeutix is DEXTENZA™ (dexamethasone ophthalmic insert) 0.4 mg. It is the first and only FDA-approved intracanalicular insert indicated for the treatment of ocular pain and inflammation after ophthalmic surgery. DEXTENZA is inserted into the lower lacrimal punctum of the eye and slowly releases dexamethasone, a corticosteroid, for up to 30 days.
In addition to DEXTENZA, Ocular Therapeutix has a robust pipeline of product candidates targeting various eye conditions. Some of the key therapeutic areas the company focuses on include glaucoma, allergic conjunctivitis, and dry eye disease.
For glaucoma, Ocular Therapeutix is developing OTX-TP, a prostaglandin analog ophthalmic insert that aims to reduce intraocular pressure by improving patient compliance with once-daily dosing. This product is intended to eliminate the burden of daily eye drops, which is a common compliance issue among glaucoma patients.
In the realm of allergic conjunctivitis, Ocular Therapeutix is developing OTX-CSI, a corticosteroid ophthalmic insert. This product is designed to provide sustained release of corticosteroids to reduce inflammation and alleviate symptoms associated with allergic reactions in the eye.
Dry eye disease is another major focus area for Ocular Therapeutix. The company is developing OTX-DED, a combination product that incorporates a preservative-free lubricant eye drop and a complementary ophthalmic insert. This product aims to provide both immediate and sustained relief for patients with dry eye disease.
Overall, Ocular Therapeutix Inc. is a leading biopharmaceutical company known for its innovative sustained-release drug delivery platform in the field of ophthalmology. The company's products and pipeline candidates have the potential to improve patient outcomes, minimize the need for frequent dosing, and enhance patient compliance for various eye diseases and conditions.
Ocular Therapeutix is primarily known for its sustained-release drug delivery platform, which enables the precise and controlled release of drugs into the eye over an extended period of time. This platform, known as the hydrogel-based technology, has the potential to revolutionize the way eye diseases are treated by eliminating the need for frequent dosing and improving patient compliance.
The hydrogel-based technology utilizes a biocompatible and bioerodible polymer that forms a gel-like matrix upon contact with tears in the eye. Drugs are then incorporated into this matrix, allowing for sustained release as the matrix gradually erodes. This approach can provide continuous drug delivery for weeks or even months, depending on the specific drug and condition being treated.
One of the flagship products developed by Ocular Therapeutix is DEXTENZA™ (dexamethasone ophthalmic insert) 0.4 mg. It is the first and only FDA-approved intracanalicular insert indicated for the treatment of ocular pain and inflammation after ophthalmic surgery. DEXTENZA is inserted into the lower lacrimal punctum of the eye and slowly releases dexamethasone, a corticosteroid, for up to 30 days.
In addition to DEXTENZA, Ocular Therapeutix has a robust pipeline of product candidates targeting various eye conditions. Some of the key therapeutic areas the company focuses on include glaucoma, allergic conjunctivitis, and dry eye disease.
For glaucoma, Ocular Therapeutix is developing OTX-TP, a prostaglandin analog ophthalmic insert that aims to reduce intraocular pressure by improving patient compliance with once-daily dosing. This product is intended to eliminate the burden of daily eye drops, which is a common compliance issue among glaucoma patients.
In the realm of allergic conjunctivitis, Ocular Therapeutix is developing OTX-CSI, a corticosteroid ophthalmic insert. This product is designed to provide sustained release of corticosteroids to reduce inflammation and alleviate symptoms associated with allergic reactions in the eye.
Dry eye disease is another major focus area for Ocular Therapeutix. The company is developing OTX-DED, a combination product that incorporates a preservative-free lubricant eye drop and a complementary ophthalmic insert. This product aims to provide both immediate and sustained relief for patients with dry eye disease.
Overall, Ocular Therapeutix Inc. is a leading biopharmaceutical company known for its innovative sustained-release drug delivery platform in the field of ophthalmology. The company's products and pipeline candidates have the potential to improve patient outcomes, minimize the need for frequent dosing, and enhance patient compliance for various eye diseases and conditions.
Ocular Therapeutix Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of eye diseases and disorders. The company employs its proprietary hydrogel technology to create sustained-release pharmaceuticals, which allow for prolonged and controlled delivery of medication directly to the eye. This approach addresses several challenges faced in traditional eye therapies, such as the need for frequent dosing, poor patient adherence, and limited bioavailability.
Key Segments
1. Ocular Drug Delivery Systems: This segment is central to Ocular Therapeutixs offerings, emphasizing its unique hydrogel platform technology. The hydrogel formulations are designed to release therapeutic agents over an extended period, thus improving patient compliance and treatment efficacy.
2. Therapeutic Areas: Ocular Therapeutix is primarily focused on diseases and conditions affecting the eye, including:
- Glaucoma: A disease characterized by increased intraocular pressure (IOP) that can lead to optic nerve damage and vision loss.
- Dry Eye Disease: A common condition where either insufficient tear production or excessive tear evaporation leads to discomfort and visual disturbances.
- Allergic Conjunctivitis: Inflammation of the conjunctiva in response to allergens, resulting in redness, itching, and tearing.
Products
1. Dextenza®: This is Ocular Therapeutixs lead product, designed to treat ocular inflammation and pain following ophthalmic surgery. Dextenza is a biodegradable punctum plug containing the corticosteroid dexamethasone. It is inserted into the tear duct, allowing for sustained release of the medication over a 30-day period. This reduces the need for topical steroids and improves patient adherence.
2. ReSure® Sealant: Ocular Therapeutix offers this proprietary ocular sealant designed to help prevent fluid and air leaks at the surgical site following cataract surgery. ReSure Sealant provides an alternative to sutures, with its hydrogel formulation conforming to the ocular surface and reducing recovery time for patients.
3. Ocular Therapeutix Pipeline Products: The company is actively developing several additional products in different stages:
- Ocular Hyaluronic Acid (HA) Products: These aim to provide relief for chronic dry eye and other ocular surface diseases by restoring moisture and creating a protective barrier on the surface of the eye.
- Glaucoma Treatments: The company may pursue sustained-release formulations targeting the management of IOP, addressing the needs of glaucoma patients who struggle with traditional drop therapies.
Services
1. Clinical Development: Ocular Therapeutix invests significant resources in clinical trials to evaluate the safety and efficacy of its products. It collaborates with healthcare providers and clinical research organizations to initiate trials that advance its pipeline and support regulatory submissions.
2. Regulatory Affairs: The company maintains a robust regulatory affairs team to navigate the complexities of FDA regulations and ensure compliance during product development and post-marketing phases. This includes preparing submissions for Investigational New Drug applications (IND) and New Drug Applications (NDA).
3. Educational Initiatives: Ocular Therapeutix is also involved in providing education to healthcare professionals about its products, focusing on the benefits of sustained-release therapies. This includes workshops, seminars, and participation in ophthalmic conferences.
Conclusion
Ocular Therapeutix Inc. stands out in the biopharmaceutical landscape with its innovative approach to managing ocular diseases. By leveraging its proprietary hydrogel technology, the company provides effective solutions for patients suffering from various eye conditions while striving to enhance the overall standard of care in ophthalmology. The combination of its therapeutic focus, product lineup, and commitment to advancing ocular health exemplifies Ocular Therapeutixs dedication to improving patient outcomes.
Key Segments
1. Ocular Drug Delivery Systems: This segment is central to Ocular Therapeutixs offerings, emphasizing its unique hydrogel platform technology. The hydrogel formulations are designed to release therapeutic agents over an extended period, thus improving patient compliance and treatment efficacy.
2. Therapeutic Areas: Ocular Therapeutix is primarily focused on diseases and conditions affecting the eye, including:
- Glaucoma: A disease characterized by increased intraocular pressure (IOP) that can lead to optic nerve damage and vision loss.
- Dry Eye Disease: A common condition where either insufficient tear production or excessive tear evaporation leads to discomfort and visual disturbances.
- Allergic Conjunctivitis: Inflammation of the conjunctiva in response to allergens, resulting in redness, itching, and tearing.
Products
1. Dextenza®: This is Ocular Therapeutixs lead product, designed to treat ocular inflammation and pain following ophthalmic surgery. Dextenza is a biodegradable punctum plug containing the corticosteroid dexamethasone. It is inserted into the tear duct, allowing for sustained release of the medication over a 30-day period. This reduces the need for topical steroids and improves patient adherence.
2. ReSure® Sealant: Ocular Therapeutix offers this proprietary ocular sealant designed to help prevent fluid and air leaks at the surgical site following cataract surgery. ReSure Sealant provides an alternative to sutures, with its hydrogel formulation conforming to the ocular surface and reducing recovery time for patients.
3. Ocular Therapeutix Pipeline Products: The company is actively developing several additional products in different stages:
- Ocular Hyaluronic Acid (HA) Products: These aim to provide relief for chronic dry eye and other ocular surface diseases by restoring moisture and creating a protective barrier on the surface of the eye.
- Glaucoma Treatments: The company may pursue sustained-release formulations targeting the management of IOP, addressing the needs of glaucoma patients who struggle with traditional drop therapies.
Services
1. Clinical Development: Ocular Therapeutix invests significant resources in clinical trials to evaluate the safety and efficacy of its products. It collaborates with healthcare providers and clinical research organizations to initiate trials that advance its pipeline and support regulatory submissions.
2. Regulatory Affairs: The company maintains a robust regulatory affairs team to navigate the complexities of FDA regulations and ensure compliance during product development and post-marketing phases. This includes preparing submissions for Investigational New Drug applications (IND) and New Drug Applications (NDA).
3. Educational Initiatives: Ocular Therapeutix is also involved in providing education to healthcare professionals about its products, focusing on the benefits of sustained-release therapies. This includes workshops, seminars, and participation in ophthalmic conferences.
Conclusion
Ocular Therapeutix Inc. stands out in the biopharmaceutical landscape with its innovative approach to managing ocular diseases. By leveraging its proprietary hydrogel technology, the company provides effective solutions for patients suffering from various eye conditions while striving to enhance the overall standard of care in ophthalmology. The combination of its therapeutic focus, product lineup, and commitment to advancing ocular health exemplifies Ocular Therapeutixs dedication to improving patient outcomes.